Arteriovenous-lymphatic endothelial cell fates are specified by the master regulators, namely, Notch, COUP-TFII, and Prox1. Whereas Notch is expressed in the arteries and COUP-TFII in the veins, the lymphatics express all 3 cell fate regulators. Previous studies show that lymphatic endothelial cell (LEC) fate is highly plastic and reversible, raising a new concept that all 3 endothelial cell fates may coreside in LECs and a subtle alteration can result in a reprogramming of LEC fate. We provide a molecular basis verifying this concept by identifying a crosscontrol mechanism among these cell fate regulators. We found that Notch signal down-regulates Prox1 and COUP-TFII through Hey1 and Hey2 and that activated Notch receptor suppresses the lymphatic phenotypes and induces the arterial cell fate. On the contrary, Prox1 and COUP-TFII attenuate vascular endothelial growth factor signaling, known to induce Notch, by repressing vascular endothelial growth factor receptor-2 and neuropilin-1. We show that previously reported podoplanin-based LEC heterogeneity is associated with differential expression of Notch1 in human cutaneous lymphatics. We propose that the expression of the 3 cell fate regulators is controlled by an exquisite feedback mechanism working in LECs and that LEC fate is a consequence of the Prox1-directed lymphatic equilibrium among the cell fate regulators. (Blood. 2010;116(1):140-150)
Kaposi's sarcoma (KS) is the most common cancer among HIV-positive patients. Histogenetic origin of KS has long been elusive due to a mixed expression of both blood and lymphatic endothelial markers in KS tumor cells. However, we and others discovered that Kaposi's sarcoma herpes virus (KSHV) induces lymphatic reprogramming of blood vascular endothelial cells by upregulating PROX1, which functions as the master regulator for lymphatic endothelial differentiation. Here, we demonstrate that the KSHV latent gene kaposin-B enhances the PROX1 mRNA stability and plays an important role in KSHV-mediated PROX1 upregulation. We found that PROX1 mRNA contains a canonical AU-rich element (ARE) in its 3′-untranslated region that promotes PROX1 mRNA turnover and that kaposin-B stimulates cytoplasmic accumulation of the ARE-binding protein HuR through activation of the p38/MK2 pathway. Moreover, HuR binds to and stabilizes PROX1 mRNA through its ARE and is necessary for KSHV-mediated PROX1 mRNA stabilization. Together, our study demonstrates that kaposin-B plays a key role in PROX1 upregulation during lymphatic reprogramming of blood vascular endothelial cells by KSHV.
Papillary thyroid cancer (PTC) is one of the most common endocrine
malignancies associated with significant morbidity and mortality. Although
multiple studies have contributed to a better understanding of the genetic
alterations underlying this frequently arising disease, the downstream molecular
effectors that impact PTC pathogenesis remain to be further defined. Here, we
report that the regulator of cell fate specification, PROX1, becomes inactivated
in PTC through mRNA downregulation and cytoplasmic mislocalization. Expression
studies in clinical specimens revealed that aberrantly activated NOTCH signaling
promoted PROX1 downregulation and that cytoplasmic mislocalization significantly
altered PROX1 protein stability. Importantly, restoration of PROX1 activity in
thyroid carcinoma cells revealed that PROX1 not only enhanced
Wnt/β-catenin signaling, but also regulated several genes known to be
associated with PTC, including thyroid cancer protein (TC)-1, SERPINA1, and
FABP4. Furthermore, PROX1 re-expression suppressed the malignant phenotypes of
thyroid carcinoma cells, such as proliferation, motility, adhesion, invasion,
anchorage-independent growth, and polyploidy. Moreover, animal xenograft studies
demonstrated that restoration of PROX1 severely impeded tumor formation and
suppressed the invasiveness and the nuclear/cytoplasmic ratio of PTC cells.
Taken together, our findings demonstrate that NOTCH-induced PROX1 inactivation
significantly promotes the malignant behavior of thyroid carcinoma, and suggest
that PROX1 reactivation may represent a potential therapeutic strategy to
attenuate disease progression
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.